Prázný, Martin
Suplotova, Lyudmila
Gumprecht, Janusz
Kamenov, Zdravko
Fülöp, Tibor
Medvedchikov, Alexey
Rosenzweig, Doron
Aleksandric, Milos
Article History
Received: 13 May 2022
Accepted: 9 September 2022
First Online: 8 October 2022
Declarations
:
: Before participating in the study, approval by Independent Ethics Committees or Institutional Review Boards was obtained in each country. The study complied with the principles of the Declaration of Helsinki. Eligible patients provided written informed consent.
: Not applicable.
: Martin Prázný has received speaker honoraria and has consulted for Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novartis, Novo Nordisk, Medtronic, MSD, Mundipharma, Sanofi, and Teva. Lyudmila Suplotova declares associations (member of advisory board, lecturer, clinical trial investigator) with the following companies: Boehringer Ingelheim, AstraZeneca, Berlin Chemie, Merck, MSD, Novartis, Novo Nordisk, STADA. Janusz Gumprecht has received fees from Abbott Diabetes Care for lecturing and participating in the advisory panels. Zdravko Kamenov declares associations (member of advisory board, lecturer, clinical trial investigator) with the following companies: Actavis, AstraZeneca, Bayer Schering, Berlin Chemie, Boehringer Ingelheim, Elli Lily, LoLi pharma, Merck, MSD, Mundi pharma, Mylan, Novartis, Novo Nordisk, Pfizer, Sandoz, Sanofi, and Servier. Tibor Fülöp reports no conflicts of interest. Alexey Medvedchikov, Doron Rosenzweig, and Milos Aleksandric are employees of Boehringer Ingelheim.